Tumor-infiltrating IL-17A⁺ cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer

References

• Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-U, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet. 2016;388(10061):2796–8. doi:10.1016/s0140-6736(16)30512-8.
   PubMed Web of Science ®Google Scholar
• Compérat E, Larré S, Roupret M, Neuzillet Y, Pignot G, Quintens H, Houéde N, Roy C, Durand X, Varinot J, et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Archiv. 2015;466(5):589–594. doi:10.1007/s00428-015-1739-2.
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–675. doi:10.1200/JCO.2001.19.3.666.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, et al. ICUD-EAU international consultation on bladder cancer 2012: chemotherapy for urothelial carcinoma—neoadjuvant and adjuvant settings. Eur Urol. 2013;63(1):58–66. doi:10.1016/j.eururo.2012.08.010.
   PubMed Web of Science ®Google Scholar
• de Mingo Pulido Á, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, Coussens LM, Ruffell B. TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer. Cancer Cell. 2018 e66;33(1):60–74. doi:10.1016/j.ccell.2017.11.019.
   PubMed Web of Science ®Google Scholar
• Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CT, Pryer N, Daniel D, Hwang E, Rugo H, Coussens L, et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014;26(5):623–637. doi:10.1016/j.ccell.2014.09.006.
   PubMed Web of Science ®Google Scholar
• Krantz D, Hartana CA, Winerdal ME, Johansson M, Alamdari F, Jakubczyk T, Huge Y, Aljabery F, Palmqvist K, Zirakzadeh AA, et al. Neoadjuvant chemotherapy reinforces antitumour T cell response in urothelial urinary bladder cancer. Eur Urol. 2018.
   PubMed Web of Science ®Google Scholar
• Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Xie H,  Fu Q, Dai B, Ye D, Xu J. Identification and validation of stromal immunotype predict survival and benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. Clin Cancer Res 2017;2018. clincanres. 2687.
   Google Scholar
• Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, Ahlfors H, Wilhelm C, Tolaini M, Menzel U, et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol. 2011;12(3):255. doi:10.1038/ni.1993.
   PubMed Web of Science ®Google Scholar
• Pappu R, Rutz S, Ouyang W. Regulation of epithelial immunity by IL-17 family cytokines. Trends Immunol. 2012;33(7):343–349. doi:10.1016/j.it.2012.02.008.
   PubMed Web of Science ®Google Scholar
• Romagnoli PA, Sheridan BS, Pham Q-M, Lefrançois L, Khanna KM. IL-17A–producing resident memory γδ T cells orchestrate the innate immune response to secondary oral Listeria monocytogenes infection. Proc Natl Acad Sci USA. 2016;113(30):8502–8507. doi:10.1073/pnas.1600713113.
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149–162. doi:10.1016/j.immuni.2011.02.012.
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B, Wrzesinski C, Borman ZA, Muranski P, Restifo NP, et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood. 2009;114(3):596–599. doi:10.1182/blood-2009-02-203935.
   PubMed Web of Science ®Google Scholar
• Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31(5):787–798. doi:10.1016/j.immuni.2009.09.014.
   PubMed Web of Science ®Google Scholar
• Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14(11):3254–3261. doi:10.1158/1078-0432.CCR-07-5164.
   PubMed Web of Science ®Google Scholar
• Oosterlinck W, Lobel B, Jakse G, Malmström P-U, Stöckle M, Sternberg C. Guidelines on bladder cancer. Eur Urol. 2002;41(2):105–112. doi:10.1016/S0302-2838(01)00026-4.
   PubMed Web of Science ®Google Scholar
• Xu L, Zhu Y, An H, Liu Y, Lin Z, Wang G, Xu J. Clinical significance of tumor-derived IL-1β and IL-18 in localized renal cell carcinoma: associations with recurrence and survival. Paper presented at: Urologic Oncology: Seminars and Original Investigations; 2015.
   Google Scholar
• Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121–1133. doi:10.1016/j.cell.2006.07.035.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector T H 17 and regulatory T cells. Nature. 2006;441(7090):235. doi:10.1038/nature04753.
   PubMed Web of Science ®Google Scholar
• Amicarella F, Muraro M, Hirt C, Cremonesi E, Padovan E, Mele V, Governa V, Han J, Huber X, Droeser RA, et al. Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut. 2017;66(4):692–704. doi:10.1136/gutjnl-2015-310016.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautès–Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717. doi:10.1038/nrclinonc.2017.101.
   PubMed Web of Science ®Google Scholar
• Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nat Immunol. 2017;18(6):612. doi:10.1038/ni.3742.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Fu Q, Chang Y, Liu Z, Zhang J, Xu L, Zhu Y, Wang Y, Zhang W, Xu J. CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer. Cancer Immunol Immunother. 2018;112.
   Google Scholar
• Kastenmüller W, Brandes M, Wang Z, Herz J, Egen JG, Germain RN. Peripheral prepositioning and local CXCL9 chemokine-mediated guidance orchestrate rapid memory CD8+ T cell responses in the lymph node. Immunity. 2013;38(3):502–513. doi:10.1016/j.immuni.2012.11.012.
   PubMed Web of Science ®Google Scholar
• Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, et al. Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301. doi:10.1038/nm.3708.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database hallmark gene set collection. Cell Syst. 2015;1(6):417–425. doi:10.1016/j.cels.2015.12.004.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, Van Der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920. doi:10.1016/S0140-6736(16)00561-4.
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76. doi:10.1016/S0140-6736(16)32455-2.
   PubMed Web of Science ®Google Scholar
• Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, Fujikado N, Tanahashi Y, Akitsu A, Kotaki H, et al. Differential roles of interleukin-17A and-17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity. 2009;30(1):108–119. doi:10.1016/j.immuni.2008.11.009.
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Kokubu F, Fujita J, S-K H, Hizawa N. Role of interleukin-17F in asthma. Inflammation Allergy-Drug Targets (Form Current Drug Targets-Inflammation Allergy). 2009;8:383–389.
   PubMedGoogle Scholar
• Dahal LN. The dichotomy of T helper 17 cells in cancer. Nat Rev Immunol. 2017;17(9):592. doi:10.1038/nri.2017.93.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):nrc3245. doi:10.1038/nrc3245.
   Web of Science ®Google Scholar
• Zhang J-X, Song W, Chen Z-H, Wei J-H, Liao Y-J, Lei J, Hu M, Chen G-Z, Liao B, Lu J, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 2013;14(13):1295–1306. doi:10.1016/S1470-2045(13)70491-1.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, Sherif A, von der Maase H, Tsukamoto T, Soloway MS, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007;69(1):62–79. doi:10.1016/j.urology.2006.10.041.
   PubMedGoogle Scholar
• Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, Kashiwagi S, Tanaka H, Hirakawa K, Ohira M. A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study. BMC Cancer. 2018;18(1):371. doi:10.1186/s12885-018-4276-y.
   PubMedGoogle Scholar